Skip to content
Search

Latest Stories

GSK closer to cracking elusive vaccine for common respiratory virus

Pharmaceutical giant GlaxoSmithKline aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

RSV is a leading cause of pneumonia in toddlers and the elderly, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since the virus was first discovered in 1956.


Companies including Pfizer, J&J, Sanofi, Moderna and AstraZeneca are also racing to get an RSV therapy or vaccine approved.

The latest GSK trial is the first to show statistically significant efficacy for RSV in adults aged 60 years and older, the British drugmaker said of the ongoing study on Friday (June 10).

If approved, the RSV vaccine is expected to generate billions for GSK, which is already the world's biggest vaccine maker by sales but has faced pressure from activist investors such as Elliott Management who have urged the London-based company to shore up its drug pipeline.

The RSV data is a critical boost to GSK's drug development success rate as it prepares to spin off its consumer health venture next month into an independent listed company called Haleon.

After the split, GSK will focus solely on vaccines and prescription drugs.

More For You

​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less